$DNA is a publicly traded company in the Technology sector. This company operates across Technology and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 2 active Congressional signals mentioning $DNA, including 2 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
HR6624 forces a structural onshoring of U.S. synthetic biology IP and manufacturing away from PRC entities. Domestic pure-plays Ginkgo Bioworks ($DNA) and Twist Bioscience ($TWST) are direct beneficiaries, while large biopharma Amgen ($AMGN) and Regeneron ($REGN) face near-term capex pressure but reduced long-term IP risk. The bill advanced out of committee with bipartisan support and has an identical Senate companion bill, increasing passage probability.
→ U.S. biopharma must onshore or nearshore synthetic biology R&D and production, increasing demand for domestic pure-play platform providers
HR5186 authorizes a DoD bioindustrial manufacturing program for defense supply chain resilience. No direct appropriation — this is a pipeline-creating authorization that positions synthetic biology ($DNA), agricultural processing ($ADM), and specialty materials ($DD) firms for future contract awards. The bill is in early legislative stage (referred to committee), but the companion NDAA FY2026 (S1071) has already become law, creating a clear legislative pathway for defense biomanufacturing funding in subsequent appropriations.
→ Creates a new DoD procurement and R&D pipeline for bioindustrial products, enabling non-dilutive government revenue for synthetic biology platform companies through OTAs, grants, and prototype contracts.